According to a new study published in the National Library of Medicine, data from six randomized controlled trials with a total of 4,586 patients with a dose of tirzepatide ranging from 5mg, 10mg, and 15mg weekly revealed that the risk ratio for developing gastroparesis was significant
Daniel Drucker [Biomarker April 2023] To date, the adverse event profile of GLP-1R agonists is characterized by relatively mild gastrointestinal (GI) side effects, such as nausea, vomiting, and diarrhea
If you are new to tirzepatide or still in the early escalation phases, stick with 10 mg/mL or 20 mg/mL
The most significant factor is rapid weight loss , which is a well-established trigger for telogen effluvium
Fatima A, Maryam A, Nadeem MS, Asmat KN